[1] WHO. Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
[2] Millington KA, Fortune SM, Low J, et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA, 2011; 108, 5730-5. doi:  10.1073/pnas.1015153108
[3] Wang X, Chen S, Xu Y, et al. Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis. Emerg Microbes Infect, 2017; 6, e48.
[4] Khalid R, Afzal M, Khurshid S, et al. Fusion Molecules of Heat Shock Protein HSPX with Other Antigens of Mycobacterium tuberculosis Show High Potential in Serodiagnosis of Tuberculosis. PLoS One, 2016; 11, e0163349. doi:  10.1371/journal.pone.0163349
[5] Anderson BL, Welch RJ, Litwin CM. Assessment of three commercially available serologic assays for detection of antibodies to Mycobacterium tuberculosis and identification of active tuberculosis. Clin Vaccine Immunol, 2008; 15, 1644-9. doi:  10.1128/CVI.00271-08
[6] Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis, 1998; 2, 200-7.
[7] Lu M, Xia ZY, Bao L. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy. Cell Immunol, 2013; 285, 111-7. doi:  10.1016/j.cellimm.2013.10.001
[8] Buddle BM, Parlane NA, Wedlock DN, et al. Overview of vaccination trials for control of tuberculosis in cattle, wildlife and humans. Transbound Emerg Dis, 2013; 60, 136-46. doi:  10.1111/tbed.2013.60.issue-s1
[9] Lu JB, Chen BW, Wang GZ, et al. Recombinant tuberculosis vaccine AEC/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect, 2015; 48, 597-603. doi:  10.1016/j.jmii.2014.03.005
[10] Metcalfe HJ, Biffar L, Steinbach S, et al. Ag85A-specific CD4(+) T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties. Vaccine, 2018; 36, 2850-4. doi:  10.1016/j.vaccine.2018.03.068
[11] Suliman S, Luabeya AKK, Geldenhuys H, et al. Dose Optimization of H56:IC31 Vaccine for TB Endemic Populations:A Double-Blind, Placebo-Controlled, Dose-Selection Trial. Am J Respir Crit Care Med, 2018; rccm. 201802-0366OC-.
[12] Penn-Nicholson A, Tameris M, Smit E, et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa:a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med, 2018; 6, 287-98. doi:  10.1016/S2213-2600(18)30077-8
[13] Van Der Meeren O, Hatherill M, Nduba V, et al. Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2018; 379, 1621-34. doi:  10.1056/NEJMoa1803484
[14] Monterrubio-Lopez GP, Gonzalez YMJA, Ribas-Aparicio RM. Identification of Novel Potential Vaccine Candidates against Tuberculosis Based on Reverse Vaccinology. Biomed Res Int, 2015; 2015, 483150. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000003892307
[15] Griffin JE, Gawronski JD, Dejesus MA, et al. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog, 2011; 7, e1002251. doi:  10.1371/journal.ppat.1002251
[16] Malen H, Berven FS, Fladmark KE, et al. Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. Proteomics, 2007; 7, 1702-18. doi:  10.1002/(ISSN)1615-9861
[17] Wang X. The identification and evaluation of 16 noval antigens from Mycobacterium tuberculosis. Doctoral dissertation of Chinese center for disease control and prevention Doctoral dissertation, 2017. (In Chinese)
[18] Health MO. Diagnositic criteria for tuberculosis in China. Ministry of Health, 2017; WS288-2017. (In Chinese)
[19] Qiu Y, Wang Y, Lin N, et al. Multicenter clinical evaluation of three commercial reagent kits based on the interferon-gamma release assay for the rapid diagnosis of tuberculosis in China. Int J Infect Dis, 2015; 40, 108-12. doi:  10.1016/j.ijid.2015.09.004
[20] Pukazhvanthen P, Anbarasu D, Basirudeen SA, et al. Assessing humoral immune response of 4 recombinant antigens for serodiagnosis of tuberculosis. Tuberculosis (Edinb), 2014; 94, 622-33. doi:  10.1016/j.tube.2014.09.006
[21] Shete PB, Ravindran R, Chang E, et al. Evaluation of antibody responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda. PLoS One, 2017; 12, e0180122. doi:  10.1371/journal.pone.0180122
[22] WHO. Guidelines Approved by the Guidelines Review Committee, in Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis: Policy Statement. 2011.
[23] Cao SH, Chen YQ, Sun Y, et al. Screening of Serum Biomarkers for Distinguishing between Latent and Active Tuberculosis Using Proteome Microarray. Biomed Environ Sci, 2018; 31, 515-26. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=bes201807004
[24] Khurshid S, Afzal M, Khalid R, et al. Potential of multi-component antigens for tuberculosis diagnosis. Biologicals, 2017; 48, 109-13. doi:  10.1016/j.biologicals.2017.04.004
[25] Tripathi DK, Srivastava K, Nagpal KL, et al. Exploration of some new secretory proteins to be employed for companion diagnosis of Mycobacterium tuberculosis. Immunol Lett, 2019; 209, 67-74. doi:  10.1016/j.imlet.2019.03.010
[26] Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol, 2017; 17, 691-702. doi:  10.1038/nri.2017.69
[27] Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev, 2014; 27, 3-20. doi:  10.1128/CMR.00034-13
[28] Luo W, Qu Z L, Xie Y, et al. Identification of a novel immunodominant antigen Rv2645 from RD13 with potential as a cell-mediated immunity-based TB diagnostic agent. J Infect, 2015; 71, 534-43. doi:  10.1016/j.jinf.2015.07.011
[29] Karbalaei Zadeh Babaki M, Soleimanpour S, Rezaee SA. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene:Biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microb Pathog, 2017; 112, 20-9. doi:  10.1016/j.micpath.2017.08.040
[30] Wang X, Zhang J, Liang J, et al. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-gamma+ IL-2+ CD4+ and IFN-gamma+ CD8+ T cells. PLoS One, 2015; 10, p. e0122560. doi:  10.1371/journal.pone.0122560
[31] Lan RY, Selmi C, Gershwin ME. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun, 2008; 31, 7-12. doi:  10.1016/j.jaut.2008.03.002
[32] Hossain MM, Norazmi MN. Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection——the double-edged sword? Biomed Res Int, 2013; 2013, 179174.
[33] Saunders BM, Frank AA, Orme IM, et al. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun, 2000; 68, 3322-6. doi:  10.1128/IAI.68.6.3322-3326.2000
[34] Jankovic D, Kullberg MC, Feng CG, et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med, 2007; 204, 273-83. doi:  10.1084/jem.20062175
[35] O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol, 2007; 7, 425-8. doi:  10.1038/nri2097
[36] Murray PJ, Wang L, Onufryk C, et al. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol, 1997; 158, 315-21. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5c3981ca3ffb0c65810e8cae246f75a8
[37] Gerosa F, Paganin C, Peritt D, et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med, 1996; 183, 2559-69. doi:  10.1084/jem.183.6.2559
[38] Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol, 2007; 178, 7222-34. doi:  10.4049/jimmunol.178.11.7222
[39] Christy AJ, Dharman K, Dhandapaani G, et al. Epitope based recombinant BCG vaccine elicits specific Th1 polarized immune responses in BALB/c mice. Vaccine, 2012; 30, 1364-70. doi:  10.1016/j.vaccine.2011.12.059
[40] Power CA, Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun, 1998; 66, 5743-50.
[41] Klinguer-Hamour C, Libon C, Plotnicky-Gilquin H, et al. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine, 2002; 20, 2743-51. doi:  10.1016/S0264-410X(02)00193-7
[42] Liu X, Da Z, Wang Y, et al. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice. Vaccine, 2016; 34, 1370-8. doi:  10.1016/j.vaccine.2016.01.049